Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum

In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical industry setting new expectations for the development of antidiabetes drugs for type 2 diabetes. This guidance expanded the scope and cost of research necessary for approval of such drugs by mandating long-...

Descripción completa

Detalles Bibliográficos
Autores principales: Cefalu, William T., Kaul, Sanjay, Gerstein, Hertzel C., Holman, Rury R., Zinman, Bernard, Skyler, Jay S., Green, Jennifer B., Buse, John B., Inzucchi, Silvio E., Leiter, Lawrence A., Raz, Itamar, Rosenstock, Julio, Riddle, Matthew C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2018
Materias:
Diabetes Care Expert Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741160/
https://www.ncbi.nlm.nih.gov/pubmed/29263194
http://dx.doi.org/10.2337/dci17-0057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741160/
https://www.ncbi.nlm.nih.gov/pubmed/29263194
http://dx.doi.org/10.2337/dci17-0057

Ejemplares similares